Tislelizumab, Lenvatinib

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Zhejiang Cancer Hospital

Conditions

Hepatocellular CarcinomaLenvatinibOxaliplatinPharmorubicinResectable Hepatocellular CarcinomaTACETislelizumab

Phase 2

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

CompletedNCT05807776

Tianjin Medical University Cancer Institute and HospitalResectable Hepatocellular Carcinoma

Start: 2023-04-24End: 2025-07-31Updated: 2026-04-01

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

RecruitingNCT05920863

Zhejiang Cancer HospitalHepatocellular Carcinoma, Lenvatinib, Oxaliplatin +3

Start: 2023-07-01End: 2025-12-31Target: 35Updated: 2025-02-11

Related Papers

Tislelizumab as monotherapy or in sequential combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma: A prospective, phase II clinical study.

Journal of Clinical Oncology2025-05-28